1. Academic Validation
  2. Molecular mechanism of Activin receptor inhibition by DLK1

Molecular mechanism of Activin receptor inhibition by DLK1

  • Nat Commun. 2025 Jul 1;16(1):5976. doi: 10.1038/s41467-025-60634-3.
Daniel Antfolk 1 Qianqian Ming 1 Anna Manturova 1 Erich J Goebel 2 Thomas B Thompson 2 Vincent C Luca 3
Affiliations

Affiliations

  • 1 Department of Immunology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • 2 Department of Molecular and Cellular Biosciences, University of Cincinnati, Cincinnati, OH, USA.
  • 3 Department of Immunology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA. vince.luca@moffitt.org.
Abstract

Delta-like non-canonical Notch ligand 1 (DLK1) influences myogenesis, adipogenesis, and Other aspects of human development through a process that is largely attributed to the downregulation of Notch signaling. Here, we show that DLK1 does not bind to Notch receptors or affect ligand-mediated Notch activation, but instead engages the TGF-β superfamily member Activin receptor type 2B (ACVR2B). The crystal structure of the DLK1-ACVR2B complex reveals that DLK1 mimics the binding mode of canonical TGF-β ligands to compete for access to ACVR2B. In functional assays, DLK1 antagonizes Myostatin-ACVR2B signaling to promote myoblast differentiation, rationalizing a mechanism for the role of DLK1 in muscle development and regeneration. Crosstalk between Notch and TGF-β is mediated by interactions between the transcriptional regulators SMAD2/3 and the Notch intracellular domain (NICD), and DLK1 inhibits SMAD2/3-NICD colocalization. These findings indicate that DLK1 acts directly on ACVR2B to inhibit signaling, whereas the observed effects on Notch may be an indirect result of DLK1 interference with NICD-SMAD complex formation.

Figures
Products